

S2 Table. Survival outcomes of the first-line regimens according to the risk group

First-line treatment	No.	Median OS (months, 95% CI)	Median PFS (months, 95% CI)
Good group (score 0-1)			
Single	371	11.3 (10.3-12.4)	4.9 (4.2-5.8)
Doublet	1,381	15.1 (14.4-15.9)	7.2 (6.9-7.5)
Doublet/Tmab	126	27.7 (24.2-31.2)	11.2 (9.0-13.3)
Doublet/Novel	124	15.0 (13.1-17.0)	7.6 (6.6-8.6)
Triplet	158	21.0 (17.4-24.6)	12.7 (6.1-19.4)
Moderate group (score 2-3)			
Single	283	7.3 (6.3-8.3)	4.0 (3.5-4.5)
Doublet	1,509	10.0 (9.5-10.5)	5.5 (5.2-5.8)
Doublet/Tmab	116	13.7 (11.1-16.2)	8.8 (7.6-10.0)
Doublet/Novel	134	10.1 (8.8-11.5)	5.9 (5.2-6.6)
Triplet	158	13.3 (12.1-14.5)	7.8 (6.9-8.6)
Poor group (score 4 or more)			
Single	118	4.4 (2.8-6.0)	3.2 (2.3-4.0)
Doublet	536	5.5 (5.0-6.0)	3.1 (2.6-3.6)
Doublet/Tmab	46	9.2 (8.1-10.4)	5.8 (5.3-6.4)
Doublet/Novel	29	6.4 (4.8-8.1)	5.1 (3.5-6.6)
Triplet	26	8.2 (6.5-9.9)	4.7 (2.4-6.9)

CI, confidence interval; Novel, novel agents in clinical trials; OS, overall survival; PFS, progression-free survival; Tmab, trastuzumab.